EntreMed (ENMD) Initiates ENMD-2076 Phase 2
EntreMed, Inc. (Nasdaq: ENMD) announced the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KaloBios Pharma (KBIO) IND for KB003 in Patients with Chronic Myelomonocytic Leukemia Gets FDA Clearance
- Steel Gains as Cold-Rolled Trade Case Filed; Hot-Rolled, Stainless Steel Cases Seen as Likely, Says Analyst (AKS) (X) (NUE) (MT) (STLD)
- Procter & Gamble (PG) Names David Taylor as Successor to CEO A.G. Lafley
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!